Artificial Intelligence

Advantage Solutions overhauls its board, adding heavyweights in capital markets and commercial strategy to navigate a pivotal transformation and retail industry shifts.

A new report reveals why insurance tech remains clunky and confusing. The problem isn't just bad UX—it's a systemic issue costing billions.

For the eighth straight year, Magna5 lands on CRN's Elite 150 list, proving its mettle by evolving its cybersecurity, AI, and compliance services.

With 66% of Gen Z learning skills online, the resume is changing. How can employers tell real expertise from noise in a new skill-based economy?

With promising preclinical data and Australian trial approval, Kivu’s KIVU-305 aims to overcome past failures in targeting aggressive solid tumors.

Rgenta Therapeutics unveils a promising oral drug that targets the genetic root of Huntington's, offering a new beacon of hope for patients.

As teen mental health struggles soar, experts offer a new playbook for parents, blending virtual care with timeless advice on connection and support.

As AI automates sensitive HR choices, a new report calls for urgent policy action to prevent bias and protect workers' health, income, and job stability.

AI-first firms face a hidden 'tax,' taking 80 days longer and paying 135% more to recover from cyberattacks, a new report from Fastly reveals.

P4ML joins the Orphan Therapeutics Accelerator to bring shelved cures to patients, leveraging a new non-profit model and expanding access to the MENA region.

The cybersecurity firm will provide quantum-resistant tech for a massive MDA program, aiming to secure critical U.S. systems against future cyber threats.

As AI adoption stalls at the pilot stage, new labs in Singapore, Japan, and the UK offer a crucial sandbox for testing high-stakes hybrid cloud deployments.

Legal tech firm DISCO reports strong growth fueled by a 600% surge in AI revenue, launching agentic AI and a disruptive new all-in-one pricing model.

With a key gene therapy approval imminent and major clinical data on deck, REGENXBIO's upcoming financial report will be a crucial test for the biotech.

Enterprise security leader TrendAI ditches rigid licenses for a credit-based model, promising agility and cost savings. Is this the future of cyber defense?

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

A new partnership is launching fully autonomous trucks on the busy Houston-Dallas route. What does this mean for logistics, safety, and Texas jobs?

Investment firm Humanoid Global unveils a bold 2026 strategy: acquire a core robotics business and tap into China's market and defense applications.

A new Dubai-based VC firm is launching with a radical model: providing startups with a 24/7 AI workforce to slash costs and accelerate growth.

A novel nasal spray for progressive MS shows it can calm brain inflammation and boost neuroprotection, offering new hope for a difficult-to-treat disease.